Basel, Switzerland
Basel, Switzerland

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, ranking number one in sales among the world-wide industry in 2013.Novartis manufactures such drugs as clozapine , diclofenac , carbamazepine , valsartan and imatinib mesylate . Additional agents include cyclosporin , letrozole , methylphenidate , terbinafine , and others.In 1996 Ciba-Geigy merged with Sandoz, with the pharmaceutical and agrochemical divisions of both staying together to form Novartis. Other Ciba-Geigy and Sandoz businesses were sold off, or, like Ciba Specialty Chemicals, were spun off as independent companies. The Sandoz brand disappeared for 3 years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Novartis divested its agrochemical and genetically modified crops business in 2000 with the spinout of Syngenta in partnership with AstraZeneca, which also divested its agrochemical business.Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations the International Federation of Pharmaceutical Manufacturers and Associations , and the Pharmaceutical Research and Manufacturers of America . Wikipedia.

Time filter
Source Type

Method for washing, with a water-based system, reusable molds for making silicone hydrogel contact lenses. The water-based washing system comprises a solvo-surfactant which is an alkyl (propylene glycol)nether wherein alkyl is a linear alkyl group having 2 to 5 carbon atoms and n is the integer 1, 2 or 3. The water-based system of the invention can effectively wash away silicone-containing components and other components of a lens formulation left behind on the molding surfaces of a reusable mold, after removing a silicone hydrogel contact lens cast molded in the reusable mold.

The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.

Novartis | Date: 2017-04-12

The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.

The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.

A solid pharmaceutical composition suitable for oral administration, comprising:

Novartis | Date: 2017-05-17

An apparatus for laser assisted eye treatment comprises: a laser device configured to provide focused laser radiation and having an adapter coupling port; an adapter module including first and second sub-modules, the first sub-module configured to detachably couple to the laser device at the adapter coupling port and having a contact surface for an eye, the second sub-module including an eye suction ring portion having a ring axis, wherein the second sub-module delimits at least one suction space, and the adapter module includes a vacuum inlet port in association with each of the at least one suction chamber, wherein the adapter module includes an evacuation path system configured to establish a vacuum communication connection between each of the at least one suction space and the associated vacuum inlet port, wherein the vacuum inlet port is provided at the first sub-module and the evacuation path system extends from the first sub-module to the second sub-module.

The disclosure relates to uses and regimens for accelerating/improving physical recovery in a patient with disuse atrophy triggered by reduced mobility due to a hip fracture and consequent major surgery, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an ActRII receptor binding molecule, an ActRII receptor antibody, such as the bimagrumab antibody.

Embodiments of the invention relate to particulate agents and compositions comprising particulate agents for inhalation, and methods for preparing such particulate agents and compositions for inhalation, as well as therapeutic methods. Embodiments of the method comprise preparing an emulsion by combining an oil phase dispersion of hydrophobic seed particles and an aqueous dispersion comprising an emulsifier and an emulsion stabilizer and preparing a feedstock comprising encapsulated particles by homogenizing the emulsion, and forming a plurality of coated particles by spray drying the feedstock, wherein resulting particles comprises a porous shell disposed on or over a core and the core comprises at least one hydrophobic seed particle.

Novartis | Date: 2017-05-03

The present invention provides peptide tags that can be linked to a therapeutic molecule in order to decrease the clearance of the therapeutic molecule from the synovial joint, thereby increasing its intra-articular half-life.

Sellers W.R.,Novartis
Cell | Year: 2011

In the era of next-generation sequencing, there are significant challenges to harnessing cancer genome information to develop novel therapies. Key research thrusts in both academia and industry will speed this transition, and lessons learned for cancer will more broadly shape the process for genetic contributions to the therapy of disease more broadly. © 2011 Elsevier Inc.

Loading Novartis collaborators
Loading Novartis collaborators